Introduction
Infected pancreatic necrosis (IPN) represents one of the most severe complications of acute pancreatitis (AP), significantly increasing morbidity and mortality. Recent clinical perspectives have shifted toward understanding the early phase of severe AP as a state of "immunoparalysis" or Compensatory Anti-inflammatory Response Syndrome (CARS). This study, the TRACE trial, investigated whether early immune enhancement using Thymosin alpha 1 (Tα1)—a peptide known to stimulate both innate and adaptive immunity—could reduce the incidence of IPN in patients with predicted severe acute necrotizing pancreatitis (ANP).
Background: The Rationale for Immune Modulation
Acute necrotizing pancreatitis involves the death of pancreatic tissue, which is highly susceptible to secondary infection. Historically, prevention strategies focused on prophylactic antibiotics or probiotics, but these have largely failed to show consistent clinical benefit or have raised safety concerns.
The hypothesis underlying this trial was that the early systemic inflammatory response in AP is followed by a rapid decline in immune competence, allowing bacteria to translocate from the gut into necrotic tissue. By administering Tα1, researchers aimed to bolster the host's immune defenses during this vulnerable window, potentially preventing the transition from sterile to infected necrosis.
Methodology
The TRACE trial was a multicenter, randomized, double-blind, placebo-controlled study conducted across 16 hospitals in China between March 2017 and December 2020.
Participant Selection
The study screened 3,569 patients, ultimately enrolling 508 participants with predicted severe ANP. Eligibility criteria included an APACHE II score of 8 or higher and admission within seven days of symptom onset. The cohort was characterized by a high prevalence of hypertriglyceridemia-induced pancreatitis (approximately 49%), followed by biliary causes (40%).
Intervention and Blinding
Patients were randomized 1:1 to receive either Tα1 or a matching saline placebo. The Tα1 group received subcutaneous injections of 1.6 mg every 12 hours for the first seven days, followed by 1.6 mg once daily for the subsequent seven days. To ensure the integrity of the results, patients, clinicians, and statisticians remained blinded to the treatment assignments throughout the study.
Outcomes
The primary endpoint was the development of IPN during the index hospital admission. IPN was confirmed through the presence of gas bubbles on CT scans or positive cultures from necrotic tissue obtained via fine-needle aspiration or surgery. Secondary outcomes included new-onset organ failure, 90-day mortality, and length of hospital stay.
Results
Despite the strong theoretical framework, the trial did not demonstrate a statistically significant benefit for Tα1 in preventing IPN.
Primary Outcome
In the Tα1 group, 40 out of 254 patients (15.7%) developed IPN, compared to 46 out of 254 patients (18.1%) in the placebo group. The absolute difference of -2.4% (95% CI -7.4% to 5.0%; p=0.47) did not reach statistical significance.
Secondary and Safety Outcomes
The results for secondary clinical markers were similarly balanced between the two groups:
- New-onset Organ Failure: 10.6% in the Tα1 group vs. 15.0% in the placebo group (p=0.15).
- 90-Day Mortality: Both groups exhibited a mortality rate of 9.1%.
- Complications: Rates of bleeding (6.3% vs. 3.5%) and gastrointestinal fistula (2.0% vs. 2.4%) showed no significant differences.
Safety monitoring indicated that Tα1 was well-tolerated, with adverse event rates comparable to the placebo group (8.3% vs. 7.5%).
Discussion
The failure of Tα1 to reduce IPN incidence in this large-scale trial contrasts with earlier animal models and a small-scale pilot study. Several factors may explain this discrepancy and provide insights for future research.
The Complexity of Human Pancreatitis
The inflammatory response in human AP is highly complex and heterogeneous. While Tα1 has shown efficacy in controlled laboratory settings, the multi-phase nature of human disease—where pro-inflammatory and anti-inflammatory responses often overlap—presents a more difficult target for single-agent immune modulation.
Timing and Dosage
The study allowed enrollment up to seven days post-symptom onset. It is possible that the "window of opportunity" for immune enhancement is much narrower, perhaps within the first 24 to 48 hours. Furthermore, the dosage used (3.2 mg/day initially) was lower than the 6.4 mg/day used in the preceding pilot study, which may have been insufficient to overcome severe immunosuppression.
Clinical Variables
The lack of standardization for therapeutic antibiotic use across the 16 participating centers may have introduced variability that masked the potential preventive effects of Tα1. Additionally, the researchers faced challenges in consistently monitoring mHLA-DR—a key biomarker of immune function—due to logistical constraints, making it difficult to verify the biological impact of the treatment on each patient's immune status.
Conclusion
The TRACE trial provides high-quality evidence that early immune enhancement with Thymosin alpha 1 at the studied dosage does not significantly reduce the risk of infected pancreatic necrosis in patients with severe acute necrotizing pancreatitis. While the treatment is safe, its routine use for this indication is not supported by the current findings. Future investigations should focus on earlier intervention windows, optimized dosing strategies, and the use of biomarkers to identify specific patient subgroups most likely to benefit from immune-modulating therapies.
Summary updated